About this trial
This project aims to establish a clinical cohort and diagnostic assessment framework by conducting a national multicenter cohort registry study. Through the collection of patients' clinical characteristics, it will achieve the registration, management, follow-up, and analysis of patients with Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years;
Patients meeting the diagnostic criteria for Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR);
Patients fully informed about the trial procedures who provide written informed consent.
Disqualifiers
Other severe comorbidities (e.g., malignant tumors, heart failure) with a life expectancy <12 months;
Known autoimmune/rheumatic diseases including systemic lupus erythematosus, Takayasu arteritis, Behçet's disease, polyarteritis nodosa, Wegener granulomatosis (granulomatosis with polyangiitis), eosinophilic arteritis, giant cell arteritis, rheumatoid arthritis, or IgG4-related disease;
Variant angina (Prinzmetal's angina);
Coronary artery dissection;
Trial population
Patients who meet the definition of Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR), that is, patients who have undergone myocardial infarction or target vessel-related revascularization ≥3 times due to coronary artery stenosis in the past year after coronary stent implantation and standard coronary heart disease conventional treatment (complete revascularization and optimal medical therapy), excluding common risk factors for coronary artery restenosis and known rheumatic autoimmune diseases, systemic vasculitis, etc.
Trial design
Cohort
Prospective
Treatments tested in this trial
Treatment made by experienced clinicians
Other interventionTreatment made by experienced clinicians
Treatment groups
Trial outcomes
Primary outcomes
Target vessel failure
Time to the incidence of target vessel failure, a composite of cardiovascular death, target vessel-related myocardial infarction, and target vessel-related revascularization.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
China National Center for Cardiovascular Diseases
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborator
The First Hospital of Jilin University
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Peking Union Medical College Hospital
Collaborator